Navigation Links
New insights into treatment options for patients suffering from severe alcoholic hepatitis
Date:4/16/2010

Vienna, Austria, Friday 16 April 2010: Results from two French studies presented today at the International Liver CongressTM 2010 press conference will help inform clinical practice in the treatment of patients with severe or acute alcoholic hepatitis.

The first study demonstrated the positive potential of performing liver transplantation for patients suffering from severe alcoholic hepatitis (SAH) earlier than the recommended 6-months rule (required minimum of recorded abstinence for an alcoholic patient to be eligible for a liver transplant). Indeed, those patients who do not respond to treatment with steroids have a 6-month survival of around 30% and most deaths actually occur within 2-months. The results show that early liver transplantation could be proposed to non-respondents, pending a very careful evaluation of selected patients.

Acute alcoholic hepatitis (AAH) however, is an absolute contraindication for liver transplantation. It has a low survival rate, with mortality remaining at around 35% at 6 months despite corticoid treatment, the current standard of care for the condition. The second study presented today will help inform a potential new treatment option for those patients who do not respond to standard treatment with corticoid. Data demonstrated that treatment with combined corticoids plus N-acetyl cysteine (C+NAC) showed an increase in survival rates. There have been few, large, well-designed trials advocating the use of N-acetyl cysteine to slow progression of liver disease. This latest study adds to the growing body of evidence in the benefits of treatment with C+NAC in patients with acute liver disease.

Professor Philippe Mathurin from the Hpital Huriez, CHRU Lille, France who presented the results commented: "Whilst the management of alcoholic hepatitis is steeped in controversy, as clinicians we have a responsibility to treat these patients in the most effective way possible, and as researchers we have a mand
'/>"/>

Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver
Source:Eurekalert

Page: 1 2

Related biology news :

1. Stomach stem cell discovery could bring cancer insights
2. KGI professor contributes new insights on jumping genes
3. Study involving more than 100 scientists provides new insights on green algae
4. New insights into how lasers cut flesh
5. Tumor genome analysis unveils new insights into lung cancer
6. New insights into the fate of antiparasitics in manure and manured soils
7. Hinode: new insights on the origin of solar wind
8. New mechanical insights into wound healing and scar tissue formation
9. Antarctic expedition provides new insights into the role of the Southern Ocean for global climate
10. New dinosaur from Mexico offers insights into ancient life on West America
11. New chemical tool kit manipulates mitochondria, reveals insights into drug toxicity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , April 27, 2015  For more than ... trade show has been the premier worldwide event for ... 2015 is a must-attend event for any local, national, ... into the emerging commercial markets and current applications of ... innovations of this projected $48 billion industry, and how ...
(Date:4/27/2015)... , Apr. 27, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... shipping to pre-order customers the first week of May, ... the month of May. Gino ... significant milestone for the company as Wocket® enters the ...
(Date:4/27/2015)... 27, 2015 Profile Solutions, Inc. (OTC: PSIQ), ... systems is pleased to announce that Dr Gerry ... and member of its scientific advisory board. ... a thought leader in technology-enhanced learning models. He was ... has published studies and books focused on online student ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... cells can grow new extensions when the amount of three ... , The research examined three related receptor proteins, called ... of rats. , When researchers increased the amount ... up to three times longer than those on nerve cells ...
... the detrimental loss of sea ice sheets in ... the scientific community have been saying for years. Now ... of Earth and Environmental Science are turning their attention to ... having similar effects in the frigid Antarctic region. ...
... tumor cells implanted in mice have shown that the ... breast cancer to the lungs. The new studies by ... genes work together to promote the growth of primary ... cancerous cells to escape into the bloodstream and penetrate ...
Cached Biology News:3 proteins may play important role in nerve-cell repair 2UTSA researchers examine effects of global warming on Antarctic 2A genetic 'gang of 4' drives spread of breast cancer 2A genetic 'gang of 4' drives spread of breast cancer 3A genetic 'gang of 4' drives spread of breast cancer 4
(Date:4/27/2015)... VANCOUVER , April 27, 2015 /PRNewswire/ - iCo ... ICOTF), today reported financial results for the year ... are expressed in Canadian dollars and presented under ... year,s phase two DME results did not provide ... but extremely undervalued assets remain at iCo Therapeutics", ...
(Date:4/27/2015)... , April 27, 2015  Edico Genome today ... geneticists from Harvard and Stanford Universities showed the ... genome sequence with 300x depth of coverage by ... to 60 hours with standard software. ... challenge, especially for individual research and clinical labs, ...
(Date:4/27/2015)... , April 27, 2015 ... release, please scroll to bottom . ... Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX ), Idera ... Corporation (NASDAQ: SNTA ), Spectrum Pharmaceuticals Inc. ... MDVN ). Free research report on Lexicon ...
(Date:4/27/2015)...  Haemonetics Corporation (NYSE: HAE ) today ... of $226.5 million, down 6%.  Excluding currency impact, ... Company reported a fourth quarter GAAP net loss ... net income, exclusive of transformation, restructuring and deal ... 1%, and adjusted earnings per share were $0.47, ...
Breaking Biology Technology:iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 2Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27
... Thompson, President,and CEO of Oncolytics Biotech Inc. (TSX: ... the Company at the BioSquare 2008 Conference on,Thursday, ... at the Congress Center in,Basel, Switzerland from March ... Oncolytics is a Calgary-based biotechnology company focused on ...
... Mass. and HEIDELBERG, Germany, March 10 febit,holding ... Ph.D., to,the newly created position of vice president, ... inc.,s U.S. headquarters, which is located near Boston ... marketing and sales initiatives for febit,s,genomics technology products ...
... - Anavex Life,Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today ... significantly delay the growth of cancerous,tumors in patient-derived ... were developed in ANAVEX labs using a sample,taken ... Clear cell sarcoma,is a rare type of melanoma ...
Cached Biology Technology:Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008 2febit Appoints Michelle Lyles, Ph.D., Vice President, Marketing and Sales 2Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 2Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 3Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 4Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 5Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 6